CureLab Oncology Files Patent Application for Groundbreaking Wound-Healing Therapy
June 30, 2024
CureLab Oncology’s Elenagen: DNA Vaccine Shows Promise in Immuno-Oncology and Beyond
August 15, 2024Digital Journal highlights CureLab Oncology's innovative approach with Elenagen
In the article "New Anti-Cancer Drug Works in Unexpected Ways," Digital Journal explores CureLab Oncology's development of Elenagen, a plasmid DNA therapy delivering the p62 gene. Contrary to initial assumptions that Elenagen functions by increasing p62 levels in recipient cells, the research reveals it reprograms aged, pro-inflammatory stem cells to adopt characteristics of youthful, anti-inflammatory ones. This reprogramming leads to the secretion of long-lasting signals that mimic Elenagen's effects, offering potential treatments for conditions beyond cancer, such as osteoporosis and metabolic disorders.
Digital Journal is a respected platform covering advancements in science and technology. Its feature on Elenagen explains the innovative nature of CureLab Oncology's research and its potential to revolutionize treatments for various diseases. The article highlights the company's commitment to exploring novel therapeutic pathways, positioning CureLab Oncology at the forefront of medical innovation.
